Advanced Search

Publications > Journals > Journal of Clinical and Translational Pathology > Special Issue

Updates of Cytopathology Reporting Systems

Submit your manuscript

  • Special Issue Information
  • Articles
Topic Editors

Cytopathology Reporting Systems provide standardized language for reporting in cytopathology practice. Standardized reporting categories allow effective and consistent communications across different institutions and disciplines, and convey unambiguous and clinically helpful information to our clinicians. Since the establishment of the Bethesda System for Reporting Cervical Cytology, other systems have followed and proved successful. The current updated Cytopathology Reporting Systems include:

1. The Bethesda System for Reporting Cervical Cytology (3rd ed, 2015)
2. The Bethesda System for Reporting Thyroid Cytopathology (3rd ed, 2023)
3. The Milan System for Reporting Salivary Gland Cytopathology (2nd ed, 2023)
4. The Paris System for Reporting Urinary Cytology (2nd, 2022)
5. The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology (1st ed, 2020) 
6. The International System for Reporting Serous Fluid Cytopathology (1st ed, 2020) 
7. The WHO Reporting System for Lung Cytopathology (1st ed, 2023) 
8. The WHO Reporting System for Pancreaticobiliary Cytopathology (1st ed, 2023) 
9. The WHO Reporting System for Lymph Node Cytopathology 
10. The WHO Reporting System for Soft Tissue Cytopathology 

For this special issue, we invite Cytopathologists to submit high-quality scientific manuscripts regarding their experience in using different cytopathology reporting systems. Potential topics include, but are not limited to:

1. Individual institution’s experience in using a particular reporting system, including the overall distribution of diagnostic categories, associated ROM (risk of malignancy), and updates about that particular reporting system

2. Cytology-histology correlation and follow-up data regarding diagnostic categories of a reporting system and lessons learned

3. Use certain parameters from the reporting system (such as percentage of atypical diagnosis or ratio of atypical/neoplastic) as quality metrics for the cytology lab

4. Use of biomarkers or molecular tests in diagnosis, prognosis, and prediction of therapeutic response in particular diagnostic categories of a reporting system

Priority will be given to articles that have significant impacts on the diagnosis and treatment of GU cancers with a high standard of peer review. All publications will be open access to all readers. All accepted papers will be highlighted in a special issue for GU pathology on our website.

Publication date: An article will be published online as soon as it is accepted.

Guest Editor

Fang Fan

Read More

Dr. Fang Fan earned her medical degree from Shanghai Medical School at Fudan University in China. She then began her two decades-long association with the University of Kansas Medical Center in Kansas City, Kansas, earning a Ph.D., completing her pathology residency and cytopathology fellowship, staying as a faculty, and ultimately rising to Director of Cytopathology and Barbara F. Atkinson Endowed Professor at the Pathology department. Dr. Fan joined City of Hope pathology department in 2021 and she is currently Clinical Professor and Director of Cytopathology at City of Hope Medical Center in Duarte, California.

Guest Editor

Guoping Cai

Read More

Dr. Cai earned his medical degree from Wenzhou Medical Univeristy in China. He completed his residency in Anatomic and Clinical Pathology at New York University Medical Center, where he also completed a fellowship in cytopathology. He is a board-certified pathologist and cytopathologist. He is currently Professor of Pathology and Associate Director of Cytopathology in the Department of Pathology, Yale University School of Medicine.

Important Dates

Submission open date: May 1, 2023

Submission deadline: November 30, 2023